Skip to main content

Helmy M Guirgis, MD

Research Reports
06/18/2019
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
...
06/18/2019
Journal of Clinical Pathways